For the attention of (FAO): Pharmacy / Dermatology Department Clinical Director
1. Is it your Trust/CCG policy to wait until 90 days post NICE guidance to fund new drugs or do they fund earlier?
2. What is your Trust/CCG policy re use of Zero Risk (ZR)/Early Use Schemes (EUS), i.e. where a medicine is made available free of charge or at a reduced price to the NHS whilst awaiting NICE/SMC approval, in lieu of NICE?
3. What is the process for getting such ZR/EUS schemes implemented/approved/signed off within your Trust/hospital? Who needs to sign the contracts for such schemes?
FOA: Dermatology Lead Pharmacist / Dermatology Department Clinical Director
4. What is your Trust’s policy re Individual Funding Request and/or Cohort Funding policy? Ref: IFR/Cohort Funding
5. Do you have a pathway/preferential prescribing list, illustrating sequential use of Biologics in Dermatology? What does this recommend?
6. How many lines/trials of biologics are allowed/funded for the management of psoriasis within your trust/CCG? What happens if a clinician needs to exceed this?
7. If there is a biologics psoriasis pathway – how often is it updated to reflect changes to NICE status of new therapies?
8. If there is no formulary/pathway – what do the Trust/CCG utilise in order to guide use of biologics in the management of psoriasis?
FAO: Dermatology Service Manager
9. How many patients attended for a new outpatient appointment in dermatology Utilising ICD-10 classification – L20 Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
10. The number of paediatric attendances of patients utilising ICD-10 classification – L20 for Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
11. Does your Trust have a paediatric dermatologist? Does your Trust have a paediatrician with a dermatology interest/specialism?